Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study

Purpose The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial 125 I implantation for prostate cancer. Methods This randomized single-center study involved...

Full description

Saved in:

Bibliographic Details
Published in:	World journal of urology Vol. 32; no. 6; pp. 1423 - 1432
Main Authors:	Shimizu, Nobutaka, Minami, Takafumi, Sugimoto, Koichi, Saito, Yoshitaka, Yamamoto, Yutaka, Hayashi, Taiji, Tsuji, Hidenori, Nozawa, Masahiro, Yoshimura, Kazuhiro, Ishii, Tokumi, Uemura, Hirotsugu, Nakamatsu, Kiyoshi
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-12-2014 Springer Nature B.V
Subjects:	Adrenergic alpha-1 Receptor Antagonists - therapeutic use Aged Brachytherapy - adverse effects Humans Indoles - therapeutic use Lower Urinary Tract Symptoms - drug therapy Lower Urinary Tract Symptoms - etiology Lower Urinary Tract Symptoms - physiopathology Male Medicine Medicine & Public Health Middle Aged Nephrology Oncology Original Article Prostatic Neoplasms - pathology Prostatic Neoplasms - physiopathology Prostatic Neoplasms - radiotherapy Quality of Life Treatment Outcome Urinary Bladder Neck Obstruction - drug therapy Urinary Bladder Neck Obstruction - etiology Urinary Bladder Neck Obstruction - physiopathology Urodynamics Urology Pressure flow study Brachytherapy Prostatic neoplasms Alpha-1 antagonists Silodosin
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Purpose The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial 125 I implantation for prostate cancer. Methods This randomized single-center study involved 105 patients (53 with and 52 without silodosin). Silodosin was postoperatively administered, daily, for 6 months (8 mg/day). Urinary symptoms and pressure flow were evaluated preoperatively and postoperatively at 1, 3, 6, and 12 months. Results At 12 months, interstitial 125 I implantation had induced a significant decrease in prostate volume (28.3 ± 11.1–20.5 ± 8.1 g in the silodosin group and 26.1 ± 9.7–17.7 ± 4.9 g in the controls) and the prostate-specific antigen level (7.1 ± 3.6–1.4 ± 1.7 ng/mL in the silodosin group and 8.1 ± 4.3–1.3 ± 1.2 ng/mL in the controls). Significant improvements in the international prostate symptom voiding subscores at 6 months and quality of life at 3 months were observed in those receiving silodosin. The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. Conclusions Silodosin temporarily improved LUTS, but did not improve the BOOI after 125 I implantation in the prostate.
AbstractList	The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial (125)I implantation for prostate cancer. This randomized single-center study involved 105 patients (53 with and 52 without silodosin). Silodosin was postoperatively administered, daily, for 6 months (8 mg/day). Urinary symptoms and pressure flow were evaluated preoperatively and postoperatively at 1, 3, 6, and 12 months. At 12 months, interstitial (125)I implantation had induced a significant decrease in prostate volume (28.3 ± 11.1-20.5 ± 8.1 g in the silodosin group and 26.1 ± 9.7-17.7 ± 4.9 g in the controls) and the prostate-specific antigen level (7.1 ± 3.6-1.4 ± 1.7 ng/mL in the silodosin group and 8.1 ± 4.3-1.3 ± 1.2 ng/mL in the controls). Significant improvements in the international prostate symptom voiding subscores at 6 months and quality of life at 3 months were observed in those receiving silodosin. The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. Silodosin temporarily improved LUTS, but did not improve the BOOI after (125)I implantation in the prostate. Purpose The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial 125 I implantation for prostate cancer. Methods This randomized single-center study involved 105 patients (53 with and 52 without silodosin). Silodosin was postoperatively administered, daily, for 6 months (8 mg/day). Urinary symptoms and pressure flow were evaluated preoperatively and postoperatively at 1, 3, 6, and 12 months. Results At 12 months, interstitial 125 I implantation had induced a significant decrease in prostate volume (28.3 ± 11.1–20.5 ± 8.1 g in the silodosin group and 26.1 ± 9.7–17.7 ± 4.9 g in the controls) and the prostate-specific antigen level (7.1 ± 3.6–1.4 ± 1.7 ng/mL in the silodosin group and 8.1 ± 4.3–1.3 ± 1.2 ng/mL in the controls). Significant improvements in the international prostate symptom voiding subscores at 6 months and quality of life at 3 months were observed in those receiving silodosin. The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. Conclusions Silodosin temporarily improved LUTS, but did not improve the BOOI after 125 I implantation in the prostate. The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial ^sup 125^I implantation for prostate cancer. This randomized single-center study involved 105 patients (53 with and 52 without silodosin). Silodosin was postoperatively administered, daily, for 6 months (8 mg/day). Urinary symptoms and pressure flow were evaluated preoperatively and postoperatively at 1, 3, 6, and 12 months. At 12 months, interstitial ^sup 125^I implantation had induced a significant decrease in prostate volume (28.3 ± 11.1-20.5 ± 8.1 g in the silodosin group and 26.1 ± 9.7-17.7 ± 4.9 g in the controls) and the prostate-specific antigen level (7.1 ± 3.6-1.4 ± 1.7 ng/mL in the silodosin group and 8.1 ± 4.3-1.3 ± 1.2 ng/mL in the controls). Significant improvements in the international prostate symptom voiding subscores at 6 months and quality of life at 3 months were observed in those receiving silodosin. The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. Silodosin temporarily improved LUTS, but did not improve the BOOI after ^sup 125^I implantation in the prostate.[PUBLICATION ABSTRACT]
Author	Saito, Yoshitaka Hayashi, Taiji Nakamatsu, Kiyoshi Yamamoto, Yutaka Sugimoto, Koichi Tsuji, Hidenori Minami, Takafumi Nozawa, Masahiro Ishii, Tokumi Shimizu, Nobutaka Yoshimura, Kazuhiro Uemura, Hirotsugu
Author_xml	– sequence: 1 givenname: Nobutaka surname: Shimizu fullname: Shimizu, Nobutaka email: shimizun@med.kindai.ac.jp organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 2 givenname: Takafumi surname: Minami fullname: Minami, Takafumi organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 3 givenname: Koichi surname: Sugimoto fullname: Sugimoto, Koichi organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 4 givenname: Yoshitaka surname: Saito fullname: Saito, Yoshitaka organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 5 givenname: Yutaka surname: Yamamoto fullname: Yamamoto, Yutaka organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 6 givenname: Taiji surname: Hayashi fullname: Hayashi, Taiji organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 7 givenname: Hidenori surname: Tsuji fullname: Tsuji, Hidenori organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 8 givenname: Masahiro surname: Nozawa fullname: Nozawa, Masahiro organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 9 givenname: Kazuhiro surname: Yoshimura fullname: Yoshimura, Kazuhiro organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 10 givenname: Tokumi surname: Ishii fullname: Ishii, Tokumi organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 11 givenname: Hirotsugu surname: Uemura fullname: Uemura, Hirotsugu organization: Department of Urology, Faculty of Medicine, Kinki University – sequence: 12 givenname: Kiyoshi surname: Nakamatsu fullname: Nakamatsu, Kiyoshi organization: Department of Radiology, Faculty of Medicine, Kinki University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24435207$$D View this record in MEDLINE/PubMed
BookMark	eNp1kE1r3DAQhkVISDZpfkAuRdCzW40-bKu3EjZpIdBLehayNdr14pVcyU7x_vp42aT0UhiYwzzvO_Bck_MQAxJyB-wzMFZ9yYwJqQoGsgAudHE4IyuQQhR1xctzsmIVl4XUtbgi1znvGIOqZOqSXHEpheKsWpGw9r5rbTvT6Gnu-uhi7gJdZrBjh2HMdAoO0yZ2YUObZNvtPG4x2WH-Si1NNri47w7o6Jg62y_Bl9i_HFlLh4Q5Twmp7-MfmsfJzR_Ihbd9xtu3fUN-Payf778XTz8ff9x_eypaxeqxaNCBAO9967RvG8aVQ9CAlteV8tq2KLTmKNEy0Krx2IBwaHXJvVS28uKGfDr1Din-njCPZhenFJaXBkquaihZDQsFJ6pNMeeE3gyp29s0G2DmaNicDJvFsDkaNocl8_GteWr26P4m3pUuAD8BeTmFDaZ_Xv-39RUmmovm
CitedBy_id	crossref_primary_10_1007_s00345_020_03398_3 crossref_primary_10_1007_s11934_021_01048_8 crossref_primary_10_1186_s13014_014_0302_7 crossref_primary_10_2147_DDDT_S373659 crossref_primary_10_1016_j_brachy_2017_12_004 crossref_primary_10_1016_j_brachy_2021_07_006 crossref_primary_10_1007_s12325_018_0854_2 crossref_primary_10_1111_luts_12402 crossref_primary_10_1016_j_brachy_2017_05_009 crossref_primary_10_1111_ijcp_12693 crossref_primary_10_1007_s11884_014_0279_y crossref_primary_10_1016_j_brachy_2014_09_009
Cites_doi	10.1016/S0360-3016(01)02812-7 10.1016/S0302-2838(02)00019-2 10.1002/nau.10066 10.1111/j.1464-410X.2005.05346.x 10.1016/j.ijrobp.2004.09.036 10.1016/j.radonc.2007.05.020 10.1016/j.juro.2013.03.110 10.1016/S0022-5347(01)62542-4 10.1016/S0360-3016(01)02657-8 10.1111/j.1464-410X.2011.10814.x 10.1016/S0090-4295(02)02142-8 10.1111/j.1464-410X.2011.10623.x 10.1016/S0090-4295(02)01840-X 10.1016/j.juro.2009.08.030 10.1200/JCO.1996.14.2.449 10.1016/j.ijrobp.2011.04.026 10.1111/j.1464-410X.2011.10800.x 10.1016/S0360-3016(99)00069-3 10.1016/j.urology.2009.05.045 10.1016/j.radonc.2008.12.009 10.1093/jjco/hyr184 10.1097/01.coc.0000225412.24750.4c 10.1016/j.ijrobp.2005.01.040 10.1200/JCO.2009.25.3245 10.1016/j.juro.2006.10.018 10.1200/JCO.1999.17.2.517 10.1016/S0360-3016(99)00525-8 10.1016/S0360-3016(02)02726-8 10.1111/j.1464-410X.2011.10827.x 10.1111/j.1442-2042.2011.02957.x
ContentType	Journal Article
Copyright	Springer-Verlag Berlin Heidelberg 2014
Copyright_xml	– notice: Springer-Verlag Berlin Heidelberg 2014
DBID	CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T5 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PQEST PQQKQ PQUKI PRINS
DOI	10.1007/s00345-014-1239-z
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts Immunology Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni)
DatabaseTitleList	MEDLINE ProQuest One Academic Eastern Edition
Database_xml	– sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1433-8726
EndPage	1432
ExternalDocumentID	3499999831 10_1007_s00345_014_1239_z 24435207
Genre	Randomized Controlled Trial Journal Article Feature
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 123 1N0 1SB 2.D 203 28- 29R 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHVUH AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 YLTOR Z45 Z7U Z7W Z7X Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 ZA5 ZGI ZMTXR ZOVNA ~EX ~KM AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7T5 7XB 8FK H94 K9. PQEST PQUKI PRINS
ID	FETCH-LOGICAL-c508t-bed131fffcd9fcb025de191ea2875f9ace3992e4ea0195bfeb13dea962f45a7f3
IEDL.DBID	AEJHL
ISSN	0724-4983
IngestDate	Mon Nov 04 10:23:32 EST 2024 Thu Nov 21 22:39:20 EST 2024 Tue Oct 15 23:53:53 EDT 2024 Sat Dec 16 12:01:20 EST 2023
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	Pressure flow study Brachytherapy Prostatic neoplasms Alpha-1 antagonists Silodosin
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c508t-bed131fffcd9fcb025de191ea2875f9ace3992e4ea0195bfeb13dea962f45a7f3
PMID	24435207
PQID	1625816081
PQPubID	36817
PageCount	10
ParticipantIDs	proquest_journals_1625816081 crossref_primary_10_1007_s00345_014_1239_z pubmed_primary_24435207 springer_journals_10_1007_s00345_014_1239_z
PublicationCentury	2000
PublicationDate	2014-12-01
PublicationDateYYYYMMDD	2014-12-01
PublicationDate_xml	– month: 12 year: 2014 text: 2014-12-01 day: 01
PublicationDecade	2010
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: Berlin
PublicationTitle	World journal of urology
PublicationTitleAbbrev	World J Urol
PublicationTitleAlternate	World J Urol
PublicationYear	2014
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	TerkMDStockRGStoneNNIdentification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostateJ Urol1998160137913821:STN:280:DyaK1cvitF2kug%3D%3D975135810.1016/S0022-5347(01)62542-4 AshDBottomleyDAl-QaisiehBCareyBGouldKHenryAA prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localized prostate cancerRadiother Oncol2007841351391760414010.1016/j.radonc.2007.05.020 YoshidaMKudohJHommaYKawabeKNew clinical evidence of silodosin, an α1A selective adrenoceptor antagonist, in the treatment for lower urinary tract symptomsInt J Urol2012193063161:CAS:528:DC%2BC38XotFKgt7k%3D2225114810.1111/j.1442-2042.2011.02957.x MatsukawaYGotohMKomatsuTFunahashiYSassaNHattoriREfficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow studyJ Urol2009182283128351983742810.1016/j.juro.2009.08.030 BucciJMorrisWJKeyesMSpadingerISidhuSMoravanVPredictive factors of urinary retention following prostate brachytherapyInt J Radiat Oncol Biol Phys20025391981200794610.1016/S0360-3016(01)02812-7 StoneNNStockRGComplication following permanent brachytherapyEur Urol2002414274331:STN:280:DC%2BD38zjtVynuw%3D%3D1207481510.1016/S0302-2838(02)00019-2 CrawfordEDKavanaghBDThe role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapyAm J Clin Oncol2006295175231702379010.1097/01.coc.0000225412.24750.4c National Comprehensive Cancer Network. http://www.nccn.com/prostate_cancer.aspx. Accessed 31 Mar 2010 StoneNNStockRGThe effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volumeJ Urol20071779259281:CAS:528:DC%2BD2sXjtF2hsrs%3D1729637710.1016/j.juro.2006.10.018 ZelefskyMJWallnerKELingCCRabenAHollisterTWolfeTGrannAGaudinPFuksZLeibelSAComparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancerJ Clin Oncol1999175175221:STN:280:DyaK1M7nvVKkuw%3D%3D10080594 AnscherMSChenLRabbaniZKangSLarrierNHuangHSamulskiTVDewhirstMWBrizelDMFolzRJVujaskovicZRecent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapyInt J Radiat Oncol Biol Phys2005622552591585093010.1016/j.ijrobp.2005.01.040 MatsudaTMarugameTKamoKKatanodaKAjikiWSobueTJapan Cancer Surveillance Research GroupCancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) projectJpn J Clin Oncol2012421391472217234710.1093/jjco/hyr184 MerrickGSButlerWMWallnerKEAllenZGalbreathRWLiefJHBrachytherapy related dysuriaBJU Int2005955976021570508710.1111/j.1464-410X.2005.05346.x ChooRDoVHerschornSDeBoerGDanjouxCMortonGChengCHBarakIPreinerJUrodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinomaInt J Radiat Oncol Biol Phys2002532902961202313210.1016/S0360-3016(02)02726-8 SchäferWAbramsPLiaoLMattiassonAPesceFSpangbergASterlingAMZinnerNRvan KerrebroeckPInternational Continence SocietyGood urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studiesNeurourol Urodyn2002212612741194872010.1002/nau.10066 BoettcherMHaselhuhnAJakseGBrehmerBKirschner-HermannsROveractive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?BJU Int2012109182418302195203910.1111/j.1464-410X.2011.10623.x AaltomaaSHKatajaVVLahtinenTPalmgrenJEForsellTEight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy–morbidity and outcome resultsRadiother Oncol2009912132161916711910.1016/j.radonc.2008.12.009 InoueSSaitoMTsounapiPDimitriadisFOhmasaFKinoshitaYSatohKTakenakaAEffect of silodosin on detrusor overactivity in the male spontaneously hypertensive ratBJU Int2012110E118E1241:CAS:528:DC%2BC38XhtFOmsrjM2214601710.1111/j.1464-410X.2011.10814.x MerrickGSButlerWMLiefJHDorseyATTemporal resolution of urinary morbidity following prostate brachytherapyInt J Radiat Oncol Bio Phys2000471211281:STN:280:DC%2BD3c3itlCisg%3D%3D10.1016/S0360-3016(99)00525-8 PardoYGuedeaFAguilóFFernándezPMacíasVMariñoAHervásAHerruzoIOrtizMJPonce de LeónJCraven-BratleJSuárezJFBoladerasAPontÀAyalaASanchoGMartínezEAlonsoJFerrerMQuality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatmentJ Clin Oncol201028468746962092146310.1200/JCO.2009.25.3245 SnyderKMStockRGBucksteinMStoneNNLong-term potency preservation following brachytherapy for prostate cancerBJU Int20121102212252273447510.1111/j.1464-410X.2011.10800.x LockeJEllisWWallnerKCavanaghWBlaskoJRisk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective studyInt J Radiat Oncol Biol Phys2002527127191184979410.1016/S0360-3016(01)02657-8 WallnerKRoyJHarrisonLTumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinomaJ Clin Oncol1996144494531:STN:280:DyaK283itlCjsg%3D%3D8636756 GrimmPBillietlBostwickDDickerAPFrankSImmerzeelJKeyesMKupelianPLeeWRMachtensSMayadevJMoranBJMerrickGMillarJRoachMStockRShinoharaKScholzMWeberEZietmanAZelefskyMWongJWentworthSVeraRLangleySComparative analysis of prostate-specific antigen-free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupBJU Int2012109Suppl 122292223922610.1111/j.1464-410X.2011.10827.x ElshaikhMAAngermeierKUlchakerJCKleinEAChidelMAMahoneySWilkinsonDAReddyCACiezkiJPEffect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapyUrology2003611521551255928710.1016/S0090-4295(02)02142-8 MerrickGSButlerWMWallnerKELiefJHGalbreathRWProphylactic versus therapeutic alpha-blockers after permanent prostate brachytherapyUrology2002606506551238592710.1016/S0090-4295(02)01840-X NagSBeyerDFriedlandJGrimmPNathRAmerican brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancerInt J Radiat Oncol Biol Phys1999447897991:STN:280:DyaK1MzhtlajtA%3D%3D1038663510.1016/S0360-3016(99)00069-3 ElshaikhMAUlchakerJCReddyCAAngermeierKWKleinEAChehadeNAltmanACiezkiJPProphylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized studyInt J Radiat Oncol Biol Phys2005621641691:CAS:528:DC%2BD2MXjsFKjsLk%3D1585091710.1016/j.ijrobp.2004.09.036 GoiYTomiyamaYNomiyaMSagawaKAikawaKYamaguchiOEffects of silodosin, a selective α1a-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstructionJ Urol2013190111611221:CAS:528:DC%2BC3sXhtFGmur7O2354510310.1016/j.juro.2013.03.110 TsumuraHSatohTIshiyamaHTabataKKotaniSMinamidaSKimuraMFujitaTMatsumotoKKitanoMHayakawaKBabaSComparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trialInt J Radiant Oncol Biol Phys201181e385e3921:CAS:528:DC%2BC3MXhtlyktL7I10.1016/j.ijrobp.2011.04.026 OkutsuHMatsumotoSHanaiTNoguchiYFujiyasuNOhtakeASuzukiMSatoSSasamataMUemuraHKuritaTEffects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstructionUrology2010752352401964730410.1016/j.urology.2009.05.045 12007946 - Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):91-8 8636756 - J Clin Oncol. 1996 Feb;14(2):449-53 22146017 - BJU Int. 2012 Jul;110(2 Pt 2):E118-24 10758313 - Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):121-8 12074815 - Eur Urol. 2002 Apr;41(4):427-33 15705087 - BJU Int. 2005 Mar;95(4):597-602 15850917 - Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):164-9 10386635 - Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):789-99 10080594 - J Clin Oncol. 1999 Feb;17(2):517-22 12559287 - Urology. 2003 Jan;61(1):152-5 19837428 - J Urol. 2009 Dec;182(6):2831-5 17604140 - Radiother Oncol. 2007 Aug;84(2):135-9 17296377 - J Urol. 2007 Mar;177(3):925-8 22172347 - Jpn J Clin Oncol. 2012 Feb;42(2):139-47 19647304 - Urology. 2010 Jan;75(1):235-40 22734475 - BJU Int. 2012 Jul;110(2):221-5 9751358 - J Urol. 1998 Oct;160(4):1379-82 11849794 - Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):712-9 19167119 - Radiother Oncol. 2009 May;91(2):213-6 21952039 - BJU Int. 2012 Jun;109(12):1824-30 12385927 - Urology. 2002 Oct;60(4):650-5 20921463 - J Clin Oncol. 2010 Nov 1;28(31):4687-96 22251148 - Int J Urol. 2012 Apr;19(4):306-16 22239226 - BJU Int. 2012 Feb;109 Suppl 1:22-9 21664068 - Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e385-92 23545103 - J Urol. 2013 Sep;190(3):1116-22 17023790 - Am J Clin Oncol. 2006 Oct;29(5):517-23 11948720 - Neurourol Urodyn. 2002;21(3):261-74 15850930 - Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):255-9 12023132 - Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):290-6 T Matsuda (1239_CR2) 2012; 42 MA Elshaikh (1239_CR6) 2003; 61 ED Crawford (1239_CR24) 2006; 29 M Yoshida (1239_CR15) 2012; 19 J Bucci (1239_CR5) 2002; 53 1239_CR1 D Ash (1239_CR23) 2007; 84 S Nag (1239_CR19) 1999; 44 H Okutsu (1239_CR29) 2010; 75 MS Anscher (1239_CR27) 2005; 62 Y Pardo (1239_CR3) 2010; 28 KM Snyder (1239_CR25) 2012; 110 S Inoue (1239_CR28) 2012; 110 GS Merrick (1239_CR12) 2002; 60 GS Merrick (1239_CR7) 2000; 47 R Choo (1239_CR17) 2002; 53 MJ Zelefsky (1239_CR11) 1999; 17 NN Stone (1239_CR21) 2007; 177 SH Aaltomaa (1239_CR22) 2009; 91 GS Merrick (1239_CR13) 2005; 95 H Tsumura (1239_CR16) 2011; 81 MA Elshaikh (1239_CR14) 2005; 62 K Wallner (1239_CR9) 1996; 14 P Grimm (1239_CR18) 2012; 109 W Schäfer (1239_CR20) 2002; 21 Y Matsukawa (1239_CR26) 2009; 182 M Boettcher (1239_CR31) 2012; 109 Y Goi (1239_CR30) 2013; 190 NN Stone (1239_CR4) 2002; 41 J Locke (1239_CR8) 2002; 52 MD Terk (1239_CR10) 1998; 160
References_xml	– volume: 53 start-page: 91 year: 2002 ident: 1239_CR5 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(01)02812-7 contributor: fullname: J Bucci – volume: 41 start-page: 427 year: 2002 ident: 1239_CR4 publication-title: Eur Urol doi: 10.1016/S0302-2838(02)00019-2 contributor: fullname: NN Stone – volume: 21 start-page: 261 year: 2002 ident: 1239_CR20 publication-title: Neurourol Urodyn doi: 10.1002/nau.10066 contributor: fullname: W Schäfer – volume: 95 start-page: 597 year: 2005 ident: 1239_CR13 publication-title: BJU Int doi: 10.1111/j.1464-410X.2005.05346.x contributor: fullname: GS Merrick – ident: 1239_CR1 – volume: 62 start-page: 164 year: 2005 ident: 1239_CR14 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2004.09.036 contributor: fullname: MA Elshaikh – volume: 84 start-page: 135 year: 2007 ident: 1239_CR23 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2007.05.020 contributor: fullname: D Ash – volume: 190 start-page: 1116 year: 2013 ident: 1239_CR30 publication-title: J Urol doi: 10.1016/j.juro.2013.03.110 contributor: fullname: Y Goi – volume: 160 start-page: 1379 year: 1998 ident: 1239_CR10 publication-title: J Urol doi: 10.1016/S0022-5347(01)62542-4 contributor: fullname: MD Terk – volume: 52 start-page: 712 year: 2002 ident: 1239_CR8 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(01)02657-8 contributor: fullname: J Locke – volume: 110 start-page: E118 year: 2012 ident: 1239_CR28 publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10814.x contributor: fullname: S Inoue – volume: 61 start-page: 152 year: 2003 ident: 1239_CR6 publication-title: Urology doi: 10.1016/S0090-4295(02)02142-8 contributor: fullname: MA Elshaikh – volume: 109 start-page: 1824 year: 2012 ident: 1239_CR31 publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10623.x contributor: fullname: M Boettcher – volume: 60 start-page: 650 year: 2002 ident: 1239_CR12 publication-title: Urology doi: 10.1016/S0090-4295(02)01840-X contributor: fullname: GS Merrick – volume: 182 start-page: 2831 year: 2009 ident: 1239_CR26 publication-title: J Urol doi: 10.1016/j.juro.2009.08.030 contributor: fullname: Y Matsukawa – volume: 14 start-page: 449 year: 1996 ident: 1239_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.2.449 contributor: fullname: K Wallner – volume: 81 start-page: e385 year: 2011 ident: 1239_CR16 publication-title: Int J Radiant Oncol Biol Phys doi: 10.1016/j.ijrobp.2011.04.026 contributor: fullname: H Tsumura – volume: 110 start-page: 221 year: 2012 ident: 1239_CR25 publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10800.x contributor: fullname: KM Snyder – volume: 44 start-page: 789 year: 1999 ident: 1239_CR19 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(99)00069-3 contributor: fullname: S Nag – volume: 75 start-page: 235 year: 2010 ident: 1239_CR29 publication-title: Urology doi: 10.1016/j.urology.2009.05.045 contributor: fullname: H Okutsu – volume: 91 start-page: 213 year: 2009 ident: 1239_CR22 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2008.12.009 contributor: fullname: SH Aaltomaa – volume: 42 start-page: 139 year: 2012 ident: 1239_CR2 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyr184 contributor: fullname: T Matsuda – volume: 29 start-page: 517 year: 2006 ident: 1239_CR24 publication-title: Am J Clin Oncol doi: 10.1097/01.coc.0000225412.24750.4c contributor: fullname: ED Crawford – volume: 62 start-page: 255 year: 2005 ident: 1239_CR27 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2005.01.040 contributor: fullname: MS Anscher – volume: 28 start-page: 4687 year: 2010 ident: 1239_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.3245 contributor: fullname: Y Pardo – volume: 177 start-page: 925 year: 2007 ident: 1239_CR21 publication-title: J Urol doi: 10.1016/j.juro.2006.10.018 contributor: fullname: NN Stone – volume: 17 start-page: 517 year: 1999 ident: 1239_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.2.517 contributor: fullname: MJ Zelefsky – volume: 47 start-page: 121 year: 2000 ident: 1239_CR7 publication-title: Int J Radiat Oncol Bio Phys doi: 10.1016/S0360-3016(99)00525-8 contributor: fullname: GS Merrick – volume: 53 start-page: 290 year: 2002 ident: 1239_CR17 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(02)02726-8 contributor: fullname: R Choo – volume: 109 start-page: 22 issue: Suppl 1 year: 2012 ident: 1239_CR18 publication-title: BJU Int doi: 10.1111/j.1464-410X.2011.10827.x contributor: fullname: P Grimm – volume: 19 start-page: 306 year: 2012 ident: 1239_CR15 publication-title: Int J Urol doi: 10.1111/j.1442-2042.2011.02957.x contributor: fullname: M Yoshida
SSID	ssj0017605
Score	2.1870883
Snippet	Purpose The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary... The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract...
SourceID	proquest crossref pubmed springer
SourceType	Aggregation Database Index Database Publisher
StartPage	1423
SubjectTerms	Adrenergic alpha-1 Receptor Antagonists - therapeutic use Aged Brachytherapy - adverse effects Humans Indoles - therapeutic use Lower Urinary Tract Symptoms - drug therapy Lower Urinary Tract Symptoms - etiology Lower Urinary Tract Symptoms - physiopathology Male Medicine Medicine & Public Health Middle Aged Nephrology Oncology Original Article Prostatic Neoplasms - pathology Prostatic Neoplasms - physiopathology Prostatic Neoplasms - radiotherapy Quality of Life Treatment Outcome Urinary Bladder Neck Obstruction - drug therapy Urinary Bladder Neck Obstruction - etiology Urinary Bladder Neck Obstruction - physiopathology Urodynamics Urology
Title	Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study
URI	https://link.springer.com/article/10.1007/s00345-014-1239-z https://www.ncbi.nlm.nih.gov/pubmed/24435207 https://www.proquest.com/docview/1625816081
Volume	32
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB60BfHi-1GtsgdPykqbbJrEW9GWIupFBW9hn1qsiTQt0v56Z_NCqR4Uckt2N5nZ7Hwzs_MtwAmC8gBnjqTCCx3KuGzRUOkWlcwT3GfKlVlMd3Dv3z0FVz1Lk-NUoYv49bzMSGYLdVXrZplU7D4zS7PnhnS-DHU0PR6rQb3bux7cVLkDv6iG9B1GWRi4ZS7zp06-W6MFiLmQHs2sTn_9P--7AWsFxiTdfFJswpKOt2Dltsiib0Pcs7wRXM5IYkg6HKFnmg5jglfBspoSW1o2fk5wQILutHyZ5XVaswvCCVo3lbwN51qR7MwPbIhrnA1M4M1sX-10rIkZJR8kI6_dgcd-7-FyQItzF6hEuDahQqu22zbGSBUaKRAVKY1uneboXXkm5FJbNlvNNLfVhsLgcu8qzcOOY5jHfePuQi1OYr0PROPHMPTXufQkc7kTChFwHyEE40K0dNCA01L-0XtOrxFVRMqZBCOUYGQlGM0b0Cw1FBV_Whq10YEL2h1ENg3Yy7VW9YTQBfFly2_AWamjLw1_G-bgT08fwqqTKxl13YTaZDzVR7CcqulxMTE_AdVj4EA
link.rule.ids	315,782,786,27934,27935,41074,42143,48345,48348,48358,49650,49653,49663,52154
linkProvider	Springer Nature
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLbYJgEX3o_xzIETKFLXprTlhmBjCNiFIXGr8oRJ0KKVCW2_HqePCTQ4gNRbm6S1U-dzbH8BOEJQHuLMkVT4kUsZlw6NlHaoZL7gAVOezPd0u_dB7zG8bFuaHK-qhcmz3auQZG6pp8VulkrFJppZnj0vopMaNCzZuVOHxvl1_6ozDR4EZTlk4DLKotCrgpk_dfJ9OZrBmDPx0XzZ6Sz_64VXYKlEmeS8mBarMKeTNZi_K-Po65C0LXMEl2OSGpINXtA3zQYJwavkWc2ILS4bPqU4IEGHWj6Pi0qt8RnhBNc3lb4OJlqR_NQPbIhWzm5N4M08s3Y01MS8pB8kp6_dgIdOu3_RpeXJC1QiYHunQquW1zLGSBUZKRAXKY2OneboX_km4lJbPlvNNLf1hsKgwfeU5tGpa5jPA-NtQj1JE70NROPHMPTYufQl87gbCRHyAEEE40I4OmzCcaWA-K0g2IinVMq5BGOUYGwlGE-asFepKC7_tSxuoQsXtk4R2zRhq1DbtCcEL4gwnaAJJ5WOvjT8bZidPz19CAvd_t1tfHvdu9mFRbdQOOp9D-rvw5Heh1qmRgflLP0ENCXkJw
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB60heLF96M-9-BJWdomG5N4EdGW-iqCCt7CPrWgiTQt0v56Z_MoinoQIbdkN8nOJvPNznzfAuwjKA9w5kgqvNChjMsmDZVuUsk8wX2mXJmt6Xbv_N5jcN62MjknJRcmq3YvU5I5p8GqNMXDxpsyjSnxzcqq2KIzq7nnhnQyC1VmSwsrUD1tX3avp4kEv6BG-g6jLAzcMrH5UydfXdM3vPktV5q5oM7Cvx9-EeYL9ElO8-myBDM6XobaTZFfX4G4bRUluByTxJC0_4Ixa9qPCR6F_mpKLOls8JTgzQkG2vJ5nDO4xseEE_R7KnntT7Qi2W4g2BD_fnbJAk9mFbejgSbmJXknmaztKjx02vdnXVrsyEAlArkhFVq13JYxRqrQSIF4SWkM-DTHuMszIZfa6txqprnlIQqDjsBVmodHjmEe9427BpU4ifUGEI0vwzCS59KTzOVOKETAfQQXjAvR1EEdDkpjRG-58EY0lVjORjDCEYzsCEaTOmyX5oqKbzCNWhjaBa0jxDx1WM9NOO0JQQ0iz6Zfh8PSXp8a_nabzT9dvQe12_NOdH3Ru9qCOSe3N5p9GyrDwUjvwGyqRrvFhP0AXPTs8w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+silodosin+in+patients+undergoing+brachytherapy%3A+a+randomized+trial+involving+a+pressure+flow+study&rft.jtitle=World+journal+of+urology&rft.au=Shimizu%2C+Nobutaka&rft.au=Minami%2C+Takafumi&rft.au=Sugimoto%2C+Koichi&rft.au=Saito%2C+Yoshitaka&rft.date=2014-12-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0724-4983&rft.eissn=1433-8726&rft.volume=32&rft.issue=6&rft.spage=1423&rft.epage=1432&rft_id=info:doi/10.1007%2Fs00345-014-1239-z&rft.externalDocID=10_1007_s00345_014_1239_z
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-4983&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-4983&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-4983&client=summon